Jeremy Perkins
Hematology & Oncology · Bethesda, MDNPI 1376573055
Payments from drug & device makers
Across 117 payments — averaging $490.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$54K
- AbbVie$314
- Sanofi$256
- Karyopharm Therapeutics Inc.$235
- Emergent Biosolutions Inc.$213
- AstraZeneca$177
- plus $2K from 35 others
Across 3 payments — averaging $900.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
What the payments were for
- Food & beverage$2,919100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 5 | $54,469 |
| AbbVie | 11 | $314 |
| Sanofi | 7 | $256 |
| Karyopharm Therapeutics Inc. | 10 | $235 |
| Emergent Biosolutions Inc. | 1 | $213 |
| AstraZeneca(2 entities) | 9 | $177 |
| Bristol Myers Squibb | 6 | $154 |
| Exelixis Inc. | 6 | $146 |
| Incyte Corporation | 7 | $143 |
| Gilead | 4 | $108 |
| Beigene USA, Inc. | 3 | $82 |
| Sobi, Inc | 3 | $78 |
| GSK | 3 | $77 |
| Daiichi Sankyo Inc. | 4 | $73 |
| Morphosys, US Inc. | 3 | $68 |
| G1 Therapeutics, Inc. | 3 | $66 |
| Genmab U.S., Inc. | 2 | $66 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $62 |
| Amgen | 3 | $46 |
| ADC Therapeutics America, Inc. | 2 | $46 |
| AVEO Pharmaceuticals, Inc. | 2 | $43 |
| CTI Biopharma Corp. | 2 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Boehringer Ingelheim | 1 | $28 |
| Mirati Therapeutics, Inc. | 1 | $27 |
| Geron Corporation | 1 | $26 |
| Tersera Therapeutics LLC | 1 | $26 |
| Fennec Pharmaceuticals, Inc. | 1 | $25 |
| Seagen Inc. | 1 | $24 |
| Coherus Oncology, Inc. | 1 | $23 |
| Immunogen, Inc. | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $22 |
| Beone Medicines USA, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| BTG International Inc. | 1 | $19 |
| Merck | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$57,388 in reported general payments places this provider in the 65th percentile of 242 hematology & oncology providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 14 | $253,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $154 | $253,99614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Bethesda
- Ralph BocciaBethesda$12.1M
- Giuseppe GiacconeBethesda$5.4M
- Tim GretenBethesda$4.2M
- Alice ChenBethesda$3.4M
- James GulleyBethesda$2.9M
- Steven PavleticBethesda$2.2M
- Sandra SwainBethesda$1M
- Susan LeitmanBethesda$252K
- Matthew HsiehBethesda$249K
- Robert KreitmanOlney$54.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.